Friday, February 2, 2024

Tyra Bioscienes Scores $200M In PIPE

Carlsbad-based Tyra Biosciences ,a company developing precision medicines for targeting Fibroblast Growth Factor Receptor (FGFR) biology, has raised $200M in a private placement (PIPE). The publicly listed company said the funding was led by RA Capital Management, and also included Boxer Capital, BVF Partners, Nextech Invest Ltd (on behalf of one or more funds managed by it), OrbiMed, 5AM Ventures, plus a number of other un-named investors. Todd Harris is CEO of TYRA.